7.17Open6.80Pre Close14 Volume191 Open Interest260.00Strike Price9.72KTurnover1760.03%IV-2.69%PremiumJan 17, 2025Expiry Date13.73Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8994Delta0.0172Gamma17.72Leverage Ratio-434.6326Theta0.0000Rho-15.93Eff Leverage0.0010Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet